Rare Medical News

Spotlight On

Alopecia totalis (AT)

Alopecia totalis is the loss of all skull and facial hair

Prevalence

30 / 100,000

Unknown

US Estimated

Unknown

Europe Estimated

Age of Onset

ageofonset-childadult.svg

ICD-10

#N/A

Inheritance

Autosomal dominant

no.svg

Autosomal recessive

no.svg

Mitochondrial/Multigenic

no.svg

X-linked dominant

no.svg

X-linked recessive

no.svg

5 Facts you should know

FACT

1

A condition characterized by the complete loss of hair on the scalp

FACT

2

An advanced form of alopecia areata

FACT

3

It is thought to be an autoimmune condition in which the immune system mistakenly attacks the hair follicles

FACT

4

Roughly 20% of affected people have a family member with alopecia

FACT

5

Among those in whom all body hair is lost, fewer than 10% recover

Alopecia totalis (AT) is also known as...

Alopecia totalis

Loss of all scalp hair

What’s your Rare IQ?

In what form of hair loss is the entire body affected?

Common signs & symptoms

Alopecia of scalp

Pathologic hair loss from scalp
Scalp hair loss

Current treatments

Everolimus(Brand name: Afinitor)

Manufactured by Novartis Pharmaceuticals Corporation
FDA-approved indication: April 2018 approved for the adjunctive treatment of adult and pediatric patients age 2 years and older with tuberous sclerosis complex (TSC)-associated partial-onset seizures. April 2012 approved for the treatment of adults with renal angiomyolipoma and tuberous sclerosis complex (TSC) not requiring immediate surgery. October 2010 approved for the treatment of patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis who require therapeutic intervention but are not candidates for curative surgical resection.
National Library of Medicine Drug Information Portal
Medline Plus Health Information

Vigabatrin(Brand name: Sabril)

Manufactured by Lundbeck
FDA-approved indication: For infantile spasms (IS) 1 month to 2 years of age
National Library of Medicine Drug Information Portal
Medline Plus Health Information

Top Clinical Trials

TitleDescriptionPhasesStatusInterventionsMore Information
PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATAThis is a global Phase 2a randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of ritlecitinib in adults aged 18 to ≤50 years of age with ≥25% scalp hair loss due to Alopecia Areata (AA).

Phase 2Active, not recruitingDrug: PF-06651600|Drug: PlaceboClick here for more information
Long-Term PF-06651600 for the Treatment of Alopecia AreataThis is a global Phase 3 study to evaluate the safety and effectiveness of an investigational study drug (PF-06651600) in adults and adolescents (12 years and older) who have alopecia areata.Phase 3Active, not recruitingDrug: PF-06651600|Biological: Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine|Biological: Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccineClick here for more information

Top Treatments in Research

AgentClass/Mechanism of ActionDevelopment StatusCompanyClinical StudiesMore Information
PF-06651600An irreversible inhibitor of JAK3 with selectivity over the other three JAK isoforms.Phase 2PfizerClick here for more informationClick here for more information